Increased survival of dopaminergic neurons in striatal grafts of fetal ventral mesencephalic cells exposed to neurotrophin-3 or glial cell line-derived neurotrophic factor
M. Espejo et al., Increased survival of dopaminergic neurons in striatal grafts of fetal ventral mesencephalic cells exposed to neurotrophin-3 or glial cell line-derived neurotrophic factor, CELL TRANSP, 9(1), 2000, pp. 45-53
The transplantation of fetal mesencephalic cell suspensions into the brain
striatal system is an emerging treatment for Parkinson's disease. However,
one objection to this procedure is the relatively poor survival of implante
d cells. The ability of neurotrophic factors to regulate developmental neur
on survival and differentiation suggests they could be used to enhance the
success of cerebral grafts. We studied the effects of neurotrophin-3 (NT-3)
or glial cell line-derived neurotrophic factor (GDNF) on the survival of d
opaminergic neurons from rat fetal ventral mesencephalic cells (FMCs) impla
nted into the rat striatum. Two conditions were tested: (a) incubation of F
MCs in media containing NT-3 and GDNF, prior to grafting, and (b) cograftin
g of FMCs with cells engineered to overexpress high levels of NT-3 or GDNF.
One week after grafting into the rat striatum, the survival of TH+ neurons
was significantly increased by pretreatment of ventral mesencephalic cells
with NT-3 or GDNF. Similarly, co-graft of ventral mesencephalic cells with
NT-3- or GDNF-overexpressing cells, but not the mock-transfected control c
ell line, increased the survival of graft-derived dopaminergic neurons. Int
erestingly, we also found that co-grafting of GDNF-overexpressing cells was
less effective than NT-3 at improving the survival of fetal dopaminergic n
eurons in the grafts, and that only GDNF induced intense TH immunostaining
in fibers and nerve endings of the host tissue surrounding the implant. Thu
s, our results suggest that NT-3, by strongly enhancing survival, and GDNF,
by promoting both survival and sprouting, may improve the efficiency of fe
tal transplants in the treatment of Parkinson's disease.